Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial
2025
Conversion Surgery in Advanced Gastric Cancer Patients Aged over 80 : Results from a Multi-Institutional Retrospective Study (OGSG2301)
進行胃癌に対する周術期capecitabine＋oxaliplatin(CapeOx)療法の術前化学療法としての有用性（OGSG1601、1701試験より）
ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer
Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for patients with gastrointestinal cancer and iron deficiency anemia undergoing chemotherapy
Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial
Identification of Prognostic Factors and Construction of Prognostic Index for Later-line Treatment in Advanced Gastric Cancer: Sub-analysis from the Phase III RINDBeRG Trial
Prognostic Implications of Neutropenia in Advanced Gastric Cancer: An Exploratory Analysis of the RINDBeRG Trial
Predictive Value of Nivolumab-Free Interval in Ramucirumab Plus Irinotecan Therapy: An Exploratory Analysis of the RINDBeRG Trial